What's in Korea Otsuka Pharmaceutical Co., Ltd.'s pipeline?

Korea Otsuka Pharmaceutical Co., Ltd. has 6 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Korea Otsuka Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Central Mental Clinic for Outpatients of Baku City, Dhaka Medical College, Gyeongsang National University Hospital, Mario Negri Institute for Pharmacological Research, Otsuka Beijing Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/korea-otsuka-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Korea Otsuka Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Korea Otsuka Pharmaceutical Co., Ltd. pipeline: 4 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone	Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone	marketed
Mucosta Tab.	Mucosta Tab.	marketed
Depakote (divalproate)	Depakote (divalproate)	marketed	Anticonvulsant / Mood stabilizer	GABA metabolism; histone deacetylase inhibition	Neurology / Psychiatry
Pletaal SR capsule	Pletaal SR capsule	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (phosphodiesterase-3)	Cardiovascular
MCT-SR	MCT-SR	phase 3	Nutritional supplement / Lipid formulation		Nutrition / Metabolic support

Therapeutic area mix

Cardiovascular · 1
Neurology / Psychiatry · 1
Nutrition / Metabolic support · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Central Mental Clinic for Outpatients of Baku City · 1 shared drug class
Dhaka Medical College · 1 shared drug class
Gyeongsang National University Hospital · 1 shared drug class
Mario Negri Institute for Pharmacological Research · 1 shared drug class
Otsuka Beijing Research Institute · 1 shared drug class
Sanofi · 1 shared drug class
The University of Texas Health Science Center at San Antonio · 1 shared drug class
University Hospitals Cleveland Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Korea Otsuka Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Korea Otsuka Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/korea-otsuka-pharmaceutical-co-ltd. Accessed 2026-05-17.